ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference
ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of "Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Established Brands business. For more information, visit .PRINCETON, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024 at 3pm EST in NYC.
新泽西州普林斯顿，2024年11月26日（环球新闻）-- ANI制药公司（"ANI"或"公司"）（纳斯达克：ANIP）今天宣布，总裁兼首席执行官Nikhil Lalwani和首席财务官Stephen Carey将于2024年12月4日下午3点在纽约市举办第36届派杰投资医疗大会的炉边聊天。
The live and archived webcast will be accessible from the Company's website at , under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days.
公司的直播和录制的网络广播将可以从公司网站访问， 在投资者部分的活动和演示下。网络广播的重播将在90天内可用。
About ANI Pharmaceuticals, Inc.
关于ANI Pharmaceuticals，Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of "Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Established Brands business. For more information, visit .
ANI制药公司（纳斯达克：ANIP）是一家多元化的生物制药公司，致力于其“服务患者，改善生活”的使命，通过开发、制造和商业化创新和高质量的治疗药物来实现。该公司专注于通过其罕见疾病业务提供可持续增长，该业务在眼科医疗、风湿科、肾病科、神经科和肺科等领域营销新产品；其仿制药业务利用研发专长、运营卓越和美国本土制造；以及其成熟品牌业务。有关更多信息，请访问 .
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
投资者关系：
英未泰客，内部沟通公司
电话：212-452-2793
E: lwilson@insitecony.com
Source: ANI Pharmaceuticals, Inc.
来源：ANI Pharmaceuticals, Inc.
